Add-On Daratumumab Triples Complete Response Rate in AL Amyloidosis
NEW YORK (Reuters Health) – Adding daratumumab to conventional therapy with cyclophosphamide, bortezomib and dexamethasone (CyBorD) nearly triples the rate
Read moreNEW YORK (Reuters Health) – Adding daratumumab to conventional therapy with cyclophosphamide, bortezomib and dexamethasone (CyBorD) nearly triples the rate
Read more